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Abstract
Myasthenia gravis (MG) is an autoimmune disease characterized by impaired neuromuscular signaling due to autoantibod-
ies targeting the acetylcholine receptor. Although its auto-antigens and effector mechanisms are well defined, the cellular 
and molecular drivers underpinning MG remain elusive. Here, we employed high-dimensional single-cell mass and spectral 
cytometry of blood and thymus samples from MG patients in combination with supervised and unsupervised machine-
learning tools to gain insight into the immune dysregulation underlying MG. By creating a comprehensive immune map, 
we identified two dysregulated subsets of inflammatory circulating memory T helper (Th) cells. These signature  ThCD103 
and  ThGM cells populated the diseased thymus, were reduced in the blood of MG patients, and were inversely correlated 
with disease severity. Both signature Th subsets rebounded in the blood of MG patients after surgical thymus removal, 
indicative of their role as cellular markers of disease activity. Together, this in-depth analysis of the immune landscape of 
MG provides valuable insight into disease pathogenesis, suggests novel biomarkers and identifies new potential therapeutic 
targets for treatment.
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Introduction
Myasthenia gravis (MG) is an antibody-mediated autoim-
mune disease affecting neuromuscular transmission. Most 
MG patients have autoantibodies recognizing the acetylcho-
line receptor (AChR), leading to potentially life-threaten-
ing muscle weakness [1]. Despite their central role in MG Bettina Schreiner and Burkhard Becher jointly supervised this 
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pathology, AChR antibody levels do not correlate well with 
disease severity or treatment responses [37], highlighting 
our lack of knowledge of the underlying mechanisms of 
the disease. There is clear evidence of the key role of the 
thymus in inducing and maintaining MG [23], and several 
studies have implicated specific cell populations besides 
antibody-producing B cells, such as type 1 T helper (Th1) 
and Th17 cells [21], regulatory T cells  (Tregs) [2] and follicu-
lar Th cells  (TFH) [47]. However, a comprehensive unbiased 
analysis of the immune cells involved in both the thymus and 
periphery of MG patients is lacking. Here, we employed an 
immunophenotyping approach to provide insight into the 
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cellular and molecular dysregulation leading to autoim-
munity in MG patients. By combining mass and spectral 
flow cytometry with data-driven machine-learning tools, we 
identified a pathogenic Th cell signature in MG that, unlike 
autoantibody levels, correlated closely with disease severity. 
Signature Th cell subsets accumulated in the MG thymus 
and were restored in the blood after thymectomy. Our study 
has identified a novel immune signature that upon valida-
tion using multicenter large-scale studies could be used as 
a biomarker to monitor disease severity and inform clinical 
management of MG patients. Moreover, these results pro-
vide a unifying analysis for further interrogation of the cel-
lular mechanisms of MG, and offer the potential to identify 
novel therapeutic targets for treatment of this disease.
Results
Major blood immune cell populations are 
comparable in MG patients and healthy controls
To generate a comprehensive immune landscape of the 
systemic immune compartment in MG, we first analyzed 
peripheral blood mononuclear cell (PBMC) samples from 
newly diagnosed steroid-free MG patients and compared 
them to age- and sex-matched healthy controls (Fig. 1a, 
Supplementary Data 1). Peripheral blood leukocytes were 
barcoded and interrogated by partially overlapping mass 
cytometry panels to fine-map immune populations with 
regards to their lineage, trafficking and activation marker 
expression and the production of 13 different cytokines at 
single-cell resolution (Fig. 1a, Supplementary Fig. 1a). We 
then randomly sampled a portion of cells from the combined 
dataset (100,000 cells) and projected them onto a Uniform 
Manifold Approximation and Projection (UMAP) [34] for 
dimensionality reduction (Fig. 1b). FlowSOM, an unsuper-
vised clustering method [19], was employed to describe the 
most abundant immune populations in the blood:  CD4+ 
T cells,  CD8+ T cells, γδ T cells,  Treg cells, natural killer 
(NK) cells, NKT cells, B cells, monocytes and dendritic 
cells (Fig. 1b). When we compared the frequencies of these 
immune cell populations, we found that they were compa-
rable between age- and sex-matched healthy controls and 
MG patients (Fig. 1c, Supplementary Fig. 1b). Even when 
we conducted a subset analysis, including those populations 
previously associated with autoantibody production, such as 
plasmablasts, memory B cells and  TFH cells (Supplemen-
tary Fig. 1c), we again did not reveal any frequency differ-
ences between patient and control groups (Fig. 1d). Thus, 
the canonical immune cell composition of blood from MG 
patients closely resembles that of healthy individuals; this 
suggests that the pathogenic changes in MG are underpinned 
either through a functional disturbance of systemic immu-
nity, or through alterations to a locally restricted immune 
compartment such as the thymus.
Peripheral Th cells of MG patients are characterized 
by reduced cytokine polarization
We then focused on functional immune profiling by identi-
fying the T cell subsets present in MG and healthy blood, 
and detecting the cytokines produced by them. We found 
that  CD4+ T cell effector subsets (Fig. 2a, Supplementary 
Fig. 2a) existed at comparable frequencies in MG patients 
and healthy controls (Supplementary Fig. 2b). However, 
when we compared cytokine profiles of antigen-experi-
enced Th subsets [effector Th  (TEff), effector memory Th 
 (TEM) and central memory Th  (TCM)] we found that MG 
patients had significantly fewer granulocyte–monocyte 
colony-stimulating factor (GM-CSF)-expressing cells than 
healthy controls (Fig. 2b, Supplementary Fig. 2c). The vast 
majority of GM-CSF-producing Th cells were from the  TEM 
population (Fig. 2c). Strikingly, although the frequency of 
GM-CSF-producing  CD4+  TEM cells was decreased in MG 
patients in general, it was especially low in the blood of 
newly diagnosed treatment-naïve MG patients with highly 
active disease compared to those with mild disease, where 
MG severity is assessed by the modified quantitative MG 
score [6] (Fig. 2c, Supplementary Fig. 2d). Thus, it appeared 
that the GM-CSF-producing  CD4+  TEM frequency is signifi-
cantly dysregulated in MG.
Fig. 1  The canonical peripheral immune landscape of MG patients 
does not differ from that of healthy individuals. a Cryopreserved 
peripheral blood mononuclear cells (PBMCs) from myasthenia gravis 
patients (MG, n = 38) and healthy controls (CTRL, n = 21) were 
labeled with a panel of antibodies recognizing either surface mark-
ers or intracellular cytokines (following brief antigen-independent 
restimulation) and data acquired by CyTOF. Thymic leukocytes 
from MG patients (n = 4) and non-MG incidental mass lesion con-
trols (n = 6) were analyzed in a similar manner by partially overlap-
ping spectral flow cytometry panels. Thymic tissue sections of MG 
patients (n = 13) and non-MG controls (n = 6) were analyzed by quan-
titative multiplexed immunofluorescence microscopy. The result-
ing datasets were analyzed using a data-driven high-dimensional 
approach using supervised and unsupervised machine-learning algo-
rithms. b UMAP of 100,0000 cells randomly sampled from the com-
bined dataset. Color code indicates FlowSOM clustering and manual 
annotation according to lineage marker expression profiles presented 
in the heatmap. Tregs regulatory T cells, DCs dendritic cells, NK natu-
ral killer. c Violin plots showing the frequency of the FlowSOM-
generated immune clusters in healthy controls and MG patients that 
did not receive immunomodulatory treatment. d Violin plots show-
ing the frequency of memory B cells  (BMEM), plasmablasts (PB) 
and peripheral follicular T helper cells  (TFH) in healthy controls and 
MG patients obtained by subclustering the B cell and  CD4+ T cell 
compartments. Violin plots contain a bold horizontal line depicting 
the respective group mean. If not indicated, the differences between 
experimental groups were statistically not significant (p > 0.05) using 
a nonparametric Mann–Whitney–Wilcoxon test with a false-discov-




To explore this possibility, we used  CD4+  TEM cytokine 
expression data to visualize clusters of cells with specific 
patterns of cytokine production in the blood of treatment-
naïve MG patients and healthy controls. We identified 13 
clusters of cytokine-producing cells, of which three were 
significantly associated with disease severity and two 
with the disease per se (Fig. 2d, Supplementary Fig. 2e). 
Interestingly, all five differentially regulated  TEM clusters 
were those that produced GM-CSF, in combination with 
tumor necrosis factor (TNF) and interleukin-2 (IL-2). Taken 
together, despite the inflammatory nature of autoimmune 
MG, these data clearly show that a general GM-CSF con-
traction within the  TEM population, rather than a specific 
cytokine profile, characterizes the blood of MG patients.
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Systemic TNF‑producing  CD103+ Th cells represent 
a disease‑specific signature population, which 
negatively correlates with the clinical disease 
severity
Alongside dysregulation of GM-CSF-producing  TEM cells, 
we analyzed trafficking molecules in the Th compartment 
and found two phenotypically distinct clusters of memory 
Th cells that were characterized by exclusive expression of 
the trafficking molecules CXCR5  (TFH) or CD103  (ThCD103) 
(Fig. 2e, Supplementary Fig. 3a and b). We next assessed 
the functional properties of the identified Th cell subsets in 
the blood. Interestingly, the blood  ThCD103 population, which 
has recently been described as a subset of formerly tissue-
resident Th cells that have reentered the circulation [29], 
demonstrated higher frequencies of GM-CSF-, TNF-, IL-
17A-, IL-22-, IL-21-, IL-13- and IL-10-producing cells than 
any other subset (Fig. 2f, Supplementary Fig. 3c). Moreo-
ver, principal component analysis of the cytokine profiles of 
the Th subsets demonstrated a remarkable heterogeneity in 
the  ThCD103 compartment, which partially overlapped with 
 TFH cells,  TEM cells and  TCM cells (Supplementary Fig. 3d). 
These results indicate that this highly inflammatory subset 
may have versatile functional properties and a remarkable 
trafficking capacity, as indicated by the  TEM phenotype com-
bined with expression of CCR2, CCR4, CXCR4 and CD103 
(Fig. 2e).
Although, overall, MG and control blood contained simi-
lar frequencies of  ThCD103 and  TFH cells across all Th cell 
populations (Supplementary Fig. 3e), when we compared 
MG patients with low and high disease burden, we uncov-
ered a significant inverse correlation between the frequencies 
of TNF-producing  ThCD103 cells (but for none of the other 12 
cytokines analyzed; Supplementary Fig. 4a) and clinical dis-
ease severity (Fig. 2g, Supplementary Fig. 4b). In contrast, 
anti-AChR autoantibody titer in serum, which is the routine 
blood biomarker for the diagnosis of MG, did not correlate 
with disease severity (Fig. 2g, right panel). Lastly, we ruled 
out the possibility that GM-CSF-producing  ThCD103 cells, 
which demonstrate an overlap with GM-CSF-expressing 
 TEM cells, are solely responsible for the contraction of GM-
CSF-expressing Th cells observed in MG (Supplementary 
Fig. 4c–f).
Collectively, while the overall immune composition in the 
blood of MG patients did not differ from healthy individuals, 
we observed consistently lower frequencies of certain patrol-
ling  TEM subsets in MG patients, such as GM-CSF-express-
ing Th cells  (ThGM) and  ThCD103 cells. This contraction of 
an inflammatory signature was particularly pronounced in 
patients with a high disease burden, again counter to our 
current understanding of the inflammatory processes in MG.
Thymi of MG patients are heavily infiltrated by Th 
cells and B cells
Given the specific contraction of circulatory  ThCD103 and 
 ThGM cells in patients with high disease severity, we specu-
lated whether these cells accumulate in the inflamed thymi 
of MG patients, characteristic for MG pathology. The thy-
mus of MG patients harbors ectopic germinal centers and 
high frequencies of autoreactive T and B lymphocytes [4, 5, 
41]. To test the notion that the thymus represents the niche 
wherein those cells reside, we collected thymic tissue from 
MG patients and sex- and age-matched controls with inci-
dental thymic mass and similar thymus pathology, but with-
out MG (Supplementary Data 2). We compared the CyTOF 
analysis of the PBMC compartment with the spectral flow 
cytometry data of the thymic immune landscape by applying 
the Scaffold framework technique [39]. This computational 
tool used the immune landscape of the blood as a reference 
Fig. 2  Reduced cytokine polarization and systemic TNF-producing 
 CD103+ T cells represent an MG-specific signature. a Heat map 
showing relative expression of the indicated activation markers 
within naïve, memory and effector subsets of  CD4+ T cells obtained 
by FlowSOM clustering. b Radar plot (left panel) representing the 
cytokine profile of antigen-experienced  CD4+ T cell subsets  (TEff, 
 TEM and  TCM). The colored line indicates the Cohen’s d effect size for 
each cytokine (MG vs. CTRL) as a deviation from the gray dashed 
reference line. Th cytokine profiles were manually annotated based 
on partially overlapping key cytokines. The violin plot (right panel) 
shows the frequency of GM-CSF+ cells among antigen-experienced 
 CD4+ T cells in control and MG patients. TCM central memory T, 
TEM effector memory T, TEff effector T, TN naive T. c Subset com-
position of the GM-CSF-producing Th cell population within all 
patients’ blood (MG and CTRL; upper panel); and relative abun-
dance of GM-CSF-producing cells within the  CD4+  TEM population 
(bottom panel) in control and MG patients (left), and in low and high 
disease severity newly diagnosed treatment-naïve MG patients (right). 
Clinical disease severity was determined by the modified quantitative 
MG score, with low disease severity scoring < 0.5, and high disease 
severity ≥ 0.5. d Cytokine expression analysis of  CD4+  TEM cells. 
FlowSOM yielded 13 cytokine expressing clusters (c1–c13; deter-
mined by consensus clustering). Corresponding expression profiles 
(left box) as well as statistical parameters (right box) are displayed. 
Blue color indicates high significance (low p value) for the compari-
son of treatment-naïve MG patients vs. CTRL, red color indicates 
high significance and high R2 value, respectively, for the correlation 
with the continuous clinical disease severity. e Heatmap comparing 
follicular Th cells  (TFH) and  CD103
+ Th cells  (ThCD103) to conven-
tional Th cells. f Row-normalized heatmap of cytokine positivity for 
13 detected cytokines among peripheral Th subsets for all patients 
present in the cohort. g Correlation between the frequency of TNF-
producing  ThCD103 cells (left panel) or serum anti-AChR antibody 
titer (right panel) and the modified quantitative MG score as a meas-
ure of clinical disease severity for newly diagnosed patients neither 
receiving immunomodulatory nor symptomatic treatment. Violin 
plots contain a bold horizontal line depicting the respective group 
mean. If not indicated, differences between experimental groups were 
statistically not significant (p > 0.05) using a nonparametric Mann–
Whitney–Wilcoxon test with a false-discovery correction accord-
ing to the Benjamini–Hochberg approach. *p < 0.05. For correlation 
analysis, statistical parameters were obtained using a linear regression 




network onto which the thymic leukocytes were projected 
(Fig. 3a). FlowSOM clustering was employed in a similar 
fashion as for the blood analysis to obtain comparable cell 
populations. Apart from mature leukocytes  (CD4+ and  CD8+ 
T cells, B cells, NK cells, NKT cells and myeloid cells), 
we identified a cluster of developing thymocytes in thymi 
(Fig. 3a). Notably, and in line with previous reports support-
ing a key role for the thymus in maintaining autoreactivity 
against AChR during MG, we observed that compared to 
control tissue, MG thymi had relatively higher frequen-
cies of B cells and Th cells, but not cytotoxic  CD8+ T cells 
(Fig. 3b). Furthermore, we observed a significant increase 
Fig. 3  Thymi of MG patients are infiltrated by Th cells and B cells. 
a Scaffold of the mass cytometry run of the peripheral immune com-
partment of MG patients and the corresponding maps of the thymic 
leukocyte landscape of MG patients and non-MG controls determined 
by flow cytometry. Heatmap below depicts FlowSOM clustering of 
thymus samples. b Violin plots showing frequency of FlowSOM-gen-
erated thymic immune clusters for MG patients and incidental non-
MG mass lesions. c Force-directed layout depicting the network of B 
cells present in the thymus. Color coding indicates FlowSOM cluster-
ing into subpopulations as shown in the heatmap (right panel). MZ 
marginal zone, BMEM memory B. d Violin plots showing frequencies 
of different B cell subpopulations in the thymus of MG patients and 
non-MG controls. Pie charts depict the median frequency of periph-
eral and thymic B cell populations in MG patients. Violin plots con-
tain a bold horizontal line depicting the respective group mean. If not 
indicated, differences between experimental groups were statistically 
not significant (p > 0.05) using a nonparametric Mann–Whitney–Wil-
coxon test with a false-discovery correction according to the Benja-
mini–Hochberg approach. *p < 0.05
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in NK cell frequency in MG thymi (Fig. 3b). Control thymi 
were matched for age (see Supplementary Data 2), thus, the 
relative decrease of immature thymocytes in thymi of MG 
patients was likely caused by an influx of circulating leuko-
cytes. First, focusing on B cells (Fig. 3c, d), we observed a 
significant increase in all subpopulations, including class-
switched  IgG+ and  IgE+/IgA+ memory B cells, in the thymi 
of MG patients compared to controls (Fig. 3d). Compared 
to the peripheral blood of MG patients, the MG thymi con-
tained relatively more memory B cells, supporting the con-
cept of a well-defined local inflammatory process underlying 
autoimmunity in MG (Fig. 3d, right panel).
Medullary regions of the thymi of MG patients are 
infiltrated by  ThCD103 and  ThGM cells
In accordance with the marked infiltration of class-switched 
memory B cells, we found increased frequencies of total 
and IL-21-expressing  TFH cells in MG patients compared 
to controls (Fig. 4a, b, Supplementary Fig. 5a). Enrichment 
of thymic  TFH cells has been described by other studies 
before and supports the notion of local B cell-supporting 
T cell pathology [11, 38]. When we measured the overall 
in situ cytokine profile of antigen-experienced Th cells, we 
did not find significant alterations in the inflamed thymus 
of MG patients compared to control thymi (Supplemen-
tary Fig. 5b); however, we found a strong trend (p = 0.052) 
towards increased frequencies of  ThGM cells, the cell popula-
tion that was specifically contracted in the systemic immune 
compartment of MG (Fig. 4c). Moreover, we could find 
 ThGM cells in medullary regions of hyperplastic thymi of 
MG patients (Fig. 4d). Focusing on the other Th cell subset 
that appeared dysregulated in the blood, we observed that 
 ThCD103 signature cells were specifically enriched in the MG 
thymus. To follow the notion that thymic  ThCD103 cells rep-
resent highly inflammatory tissue-resident memory Th cells 
that could reenter the circulation and give rise to  ThCD103 
cells found in the peripheral blood, we performed a detailed 
phenotypic comparison between thymic and blood  ThCD103 
cells,  TFH cells and conventional Th cells. In line with previ-
ous reports [30, 45, 48], thymic  ThCD103 cells expressed the 
tissue-retention molecule CD69 that was absent in the blood 
counterpart, but demonstrated a shared activated memory 
phenotype with higher expression of IL-2 and TNF than  TFH 
or conventional Th cells (Fig. 4e, Supplementary Fig. 5c). 
Furthermore, expression of CCR4 in the  ThCD103 cluster in 
the blood (Fig. 4e) supported the migratory capacity of these 
cells and their ability to sense CCL17 and CCL22; these 
chemokines are abundant in the thymic medulla where they 
are secreted by macrophages and dendritic cells and provide 
medullary entry sites for thymocytes during thymic develop-
ment [7, 24, 25]. Interestingly, thymic  ThCD103 cells shared 
characteristics with  TFH cells such as high PD-1 expression 
and secretion of IL-21 but could be distinguished from  TFH 
cells due to the absence of ICOS, the higher expression of 
IL-17A and IL-2 and the exclusive expression of CD103 
(Fig. 4e). To increase the number of analyzed samples, we 
validated the enrichment of  ThCD103 cells in thymic sections 
of 13 MG patients and 6 controls by multiplexed quantita-
tive histology and located  ThCD103 cells within B cell-rich 
medullary regions of MG thymi (Fig. 4f, Supplementary 
Fig. 5d–f, Supplementary Data 3). Together with the con-
traction of TNF-producing  CD103+ Th cells in the systemic 
compartment of MG patients, these findings support a patho-
genic role of tissue-resident Th cells in locally driven B cell 
pathology in MG.
ThCD103 and  ThGM cells rebound in the blood of MG 
patients after thymectomy
The specific contraction of  ThCD103 and  ThGM cells in the 
systemic immune compartment in conjunction with an 
expansion of the signature cells in the inflamed thymus of 
MG patients points towards a pathogenic local retention of 
those cells within the inflamed thymus, rather than a global 
dysregulation of cell frequencies per se. To test this hypoth-
esis, we measured the frequencies of the identified signature 
subsets in the blood after therapeutic thymectomy; the surgi-
cal removal of the inflammatory thymic niche. In thymec-
tomized MG patients, we observed significant decreases 
in the relative frequency of  TEff coupled with expansion 
of  TEM populations in blood compared to no thymectomy 
control MG patients (Supplementary Fig. 6a). Notably, the 
increase of  TEM cells after thymectomy followed the oppo-
site trend when comparing MG patients to healthy controls 
(Supplementary Fig. 2b). Most importantly, we found sys-
temic expansion of the inflammatory signature  ThCD103 
and  ThGM populations in athymic patients (Fig. 4g), even 
though timepoints for blood sampling after thymectomy 
ranged from several months to several years (Supplementary 
Data 1). Interestingly, the high levels of the thymus tissue 
regenerative cytokine IL-22 [14] produced by  ThCD103 cells 
were markedly reduced in MG patients previously treated 
with thymectomy (Fig. 4g, Supplementary Fig. 6b). Since 
thymectomy released signature cells from the thymus, which 
could spread to secondary niches such as lymph nodes and 
bone marrow via blood circulation [16, 17], we lastly inves-
tigated whether  ThCD103 and  ThGM cells in the blood were 
suppressed by standard MG immunotherapy. Due to the lack 
of targeted immunotherapies in MG, broad immunosuppres-
sive agents like azathioprine, a purine synthesis inhibitor, 
are administered to stabilize the patients [20]. Coinciding 
with immunosuppression, we observed a significant reduc-
tion in the relative frequency of  ThCD103 cells in the blood 
in patients treated with azathioprine (Fig. 4h). Azathioprine 





driven by thymectomy (Fig. 4h). However, the biggest effect 
of azathioprine treatment was on the NK cell compartment, 
especially reducing the  CD56dim NK cell population (Sup-
plementary Fig. 6c and d). This observation is in line with 
the increased risk of azathioprine-treated patients to develop 
recurrent viral infections and virus-induced malignancies 
[31] highlighting the need for more tailored therapeutic 
interventions.
Discussion
Our single-cell profiling study provides novel insights into 
Th cell-driven MG immunopathology in the thymic niche, 
and its reflection in the systemic circulation. Using unsu-
pervised machine-learning tools, we identified two subsets 
of Th cells:  ThGM and  ThCD103, which were enriched in 
the inflamed thymi of MG patients, and thus, appeared in 
lower numbers in the blood. Moreover, the frequencies of 
both populations correlated with the clinical disease sever-
ity of MG patients, unlike the amount of serum anti-AChR 
antibodies [37]. In line with the inflammatory phenotype 
of  ThGM cells, a previous study reported GM-CSF as a 
hallmark cytokine expressed in AChR-reactive Th cells in 
MG patients [10]. The previous study incorporated antigen-
specific T cell libraries and found that, alongside GM-CSF, 
autoreactive T cells also produced IL-17 and IFN-γ. In 
addition, we pinpointed IL-22 expression to our signature 
 ThCD103 cells, similar to previous findings in skin  ThCD103 
cells [29]. Of note, IL-22 receptor expression is essentially 
restricted to epithelial and stromal cells, including those of 
the thymic tissue [13, 14]. Some data suggest that IL-22 has 
a dual role locally, as it is linked to chronic inflammation but 
is also essential for thymic regenerative processes limiting 
tissue injury [14, 46].
Surgical removal of the thymus has long been a standard 
treatment for MG, and the recently published multicenter 
randomized MGTX phase 3 trial confirmed the beneficial 
long-term effects of this procedure compared to oral steroids 
alone in MG patients [42]. It is thought that its efficacy is 
based on the removal of ectopic germinal centers and local 
pathogenic cells that drive the production of anti-AChR 
autoantibodies [20]. In our study, the signature populations 
rebounded in the blood after surgical removal of the inflam-
matory niche supporting the notion of pathological inflam-
matory leukocyte retention in the thymus during MG. Robat-
Jazi and colleagues found significantly decreased IL-22+ Th 
cells in the blood of MG patients after thymectomy (com-
pared to before thymectomy) [35], which is in accordance 
with our results of reduced IL-22 production by  ThCD103 
cells after removal of the thymus.
From a clinical viewpoint, our study identifies the TNF-
producing  ThCD103 cell subset as a promising candidate as 
a cellular marker of disease severity in MG which should 
be validated in further studies. CD103 (integrin αEβ7) 
normally retains T cells within epithelial-rich tissues via 
binding to E-cadherin which is highly expressed in thymic 
medullary regions [32]. Several investigations have shown 
that the presence of such cytokine-secreting  CD103+ tissue-
resident memory Th cells is associated with poor outcomes 
in chronic inflammatory skin diseases such as psoriasis [8], 
vitiligo [12] and alopecia areata [43]. In addition, in the gut, 
a potential pro-inflammatory role has been allocated to the 
 ThCD103 subset [33]. More recently, Zundler and colleagues 
reported that  CD103+ tissue-resident memory Th cells accu-
mulated in the mucosa of patients with inflammatory bowel 
disease, and that the presence of  CD69+  ThCD103 cells was 
predictive of flares [48].
Even though the expression of CD103 on T cells has been 
clearly associated with tissue residency, the function of the 
circulating  CD103+ Th population remains considerably less 
defined. A recent study shed more light on their enigmatic 
Fig. 4  Signature Th cells are enriched in medullary regions of MG 
thymi and rebound in the blood after thymectomy. a Heatmap of sur-
face markers and cytokine expression profiles of FlowSOM-generated 
Th subsets. b Violin plots comparing the frequencies of  TFH cells and 
the corresponding frequency of IL-21 expression among  TFH cells in 
MG patients vs non-MG patients. c Violin plot showing the frequency 
of GM-CSF expressing Th cells  (ThGM) and  ThCD103 cells in the 
thymi of MG and non-MG patients. d Immunofluorescence labeling 
of medullary thymic regions showing GM-CSF (red), CD4 (green), 
CD3 (magenta) and DAPI (blue). Samples from 7 MG patients and 
5 non-MG controls were analyzed. Scale bar: 30 µm. Images of the 
single labels are enlargements of specified regions. Representative 
images of two independent experiments (1 slide with 3 sections/
patient each) are shown. Left: MG, early onset, female MG patient 
without immunosuppressive therapy and thymus follicular hyperpla-
sia, right: CTRL, patient with incidental mass, residual thymus tissue. 
HC Hassall’s corpuscle. e Heatmap of surface markers and cytokine 
expression profiles of FlowSOM-generated Th subsets in blood and 
thymus (left panel). Thymic expression profiles from both panels 
were clustered analogously using FlowSOM and displayed as com-
bined expression profiles. Scaffold of the blood and thymic Th cell 
compartment in MG patients (right panel). Color overlay depicts 
expression of CD103 and CD69. f Heatmap of expression profiles 
of FlowSOM-generated cell clusters for quantitative immunofluores-
cence data of thymic regions after cell segmentation (middle panel). 
Colors correspond to the populations shown in Fig. S5f. Violin plots 
showing the frequency of  ThCD103 cells within  DAPI
+ cells of MG 
patients and incidental mass lesion controls (right panel). PANCK 
pan-Cytokeratin. g Violin plots showing the frequency of  ThGM and 
 ThCD103 cells, and the frequency of IL-22 production within  ThCD103 
cells, in the blood of MG patients with or without thymectomy that 
did not receive further immunomodulatory treatment. h Violin plots 
showing the frequency of  ThCD103 and  ThGM cells in the blood of 
MG patients without treatment or with thymectomy (TMC) and/or 
azathioprine (AZA) treatment. Violin plots contain a bold horizon-
tal line depicting the respective group mean. If not indicated, differ-
ences between experimental groups were statistically not significant 
(p > 0.05) using a nonparametric Mann–Whitney–Wilcoxon test with 
a false-discovery correction according to the Benjamini–Hochberg 




role, demonstrating that skin-resident  CD69+  CD103+ Th 
cells can downregulate the tissue-retention marker CD69, 
reenter the circulation and migrate to secondary human 
skin locations [29]. This is in accordance with the predomi-
nant  TEM phenotype, versatile cytokine profile, the broad 
expression of trafficking receptors and the exclusive expres-
sion of CD69 in the tissue but not in the circulation that we 
observed in the  ThCD103 cell subset. One might speculate 
that the circulating properties of both Th subsets represent a 
shuttle between the origin of disease pathology and second-
ary sites of chronic pathogenic antibody production (in par-
ticular after thymectomy) as suggested by murine xenograft 
and local infection models [28, 29]. As a proof of principle, 
we demonstrated that both dysregulated memory Th subsets, 
 ThGM and  ThCD103, were indeed effective targets of long-
term immunosuppression by azathioprine in steroid-free MG 
patients. Counter-intuitively, both MG treatment approaches, 
thymectomy and azathioprine, modulated the frequency of 
signature cells in the blood in opposite directions, indicating 
two distinct mechanisms of action. Thymectomy abrogates 
the retention of inflammatory cells in the thymus thereby 
increasing signature Th cells in the blood, whereas azathi-
oprine halts cell replication and triggers apoptosis in leu-
kocytes [9]: the combination of these therapies, therefore, 
both removes pathogenic cells in the thymus and decreases 
Th signature cells in the circulation. Of note, perioperative 
high-dose immunosuppression has been shown by others to 
give a favorable clinical response compared to thymectomy 
alone [44].
Therefore, novel therapeutic interventions aimed at 
depleting or reducing  ThGM or  ThCD103 may improve the 
outcome of MG treatment. One such approach that is cur-
rently being developed is the use of specific anti-integrins, 
controlling both inflammatory effects and immune cell traf-
ficking: Etrolizumab, a monoclonal antibody targeting the 
two integrins CD103 and α4β7, led to clinical remission in 
patients with ulcerative colitis in a phase 2 trial, and con-
secutive phase 3 trials are ongoing [40].
Additional work is required to validate the applicability of 
the identified signature as a therapeutic target or biomarker 
for MG disease progression and response to therapy. Due to 
the heterogenous nature of the disease, it remains unclear 
whether the identified Th cell signature is restricted to anti-
AChR-antibody-positive MG patients, that we exclusively 
focused on in this study, or if it can be generalized to other 
MG forms, not involving the thymus. For example, anti-
Muscle-Specific Kinase (MuSK)-positive antibody and 
seronegative MG patients were not included in this study. 
In line with this notion, a subject for future studies is to 
further validate the specificity of the signature compared 
to other autoimmune diseases such as multiple sclerosis, 
neuromyelitis optica spectrum disorders or systemic lupus 
erythematosus. Even though a direct comparison between 
the disease signatures is pending, previous studies regarding 
disease signatures across autoimmune diseases suggest that 
there is no major overlap [18, 22].
Despite these major limitations, our report represents, 
to our knowledge, to date the most comprehensive map of 
the systemic immune compartment and the disease-driving 
thymus in MG patients. Moreover, it represents a major 
conceptual advance with the potential to be translated into 
the clinic, upon further validation using large-scale studies, 
for the therapeutic targeting of MG, as well as biomarker 
development.
Materials and methods
Healthy donors and MG patient samples
The study was approved by the Ethics Commission Zurich, 
Switzerland. MG patients (n = 21 healthy controls and n = 38 
MG patients) were recruited and upon written informed con-
sent blood and thymus samples were obtained at the Neu-
romuscular Center and the Department of Thoracic Surgery 
of the University Hospital Zurich, Switzerland. PBMC and 
serum samples were isolated at the University of Zurich 
within 12 h of blood collection. Fresh thymus tissue was 
obtained from patients undergoing elective thymectomy, in 
which thymus is routinely discarded (n = 6 non-MG controls 
versus n = 5 MG patients). Furthermore, we retrospectively 
examined formalin-fixed thymectomy samples provided by 
the tissue biobank of the Department of Pathology (Univer-
sity Hospital Zurich) by multiplexed immunofluorescence 
(Supplementary Data 3; n = 6 non-MG controls and n = 13 
MG patients). Standard histopathological analysis of thymus 
tissue was performed by a clinical pathologist independ-
ent of the study. Samples from both sexes were included 
in the study. Ages ranged from 23 to 91 years. Diagnosis 
of MG was based on typical clinical symptoms, a positive 
anti-AChR antibody test in the serum, a positive electro-
physiological measurement, and response to treatment with 
acetylcholinesterase inhibitors. The diagnosis was confirmed 
by a neurologist with experience in the care of these patients. 
No seronegative or anti-MuSK-positive MG patients were 
included in the study. Healthy controls were age- and sex-
matched, had no evidence of acute or chronic infection and 
were not receiving immunomodulatory therapy. In addition, 
patients with an (incidental) thymic mass or thymoma and 
without MG were included in the study (Supplementary Data 
2). For the blood comparison of MG patients to healthy con-
trols, only patients that were not treated with immunomodu-
latory drugs or thymectomy were considered (n = 21 healthy 
controls and n = 22 MG patients). For correlations with the 
patients’ clinical disease, severity exclusively untreated MG 
patients (excluding symptomatically treated patients; n = 12) 
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were considered and the continuous relative quantitative 
Besinger score was used as a measure of disease severity [6]. 
The Besinger score is a quantitative MG scoring system that 
has been adapted and slightly expanded by the MG Foun-
dation of America (MGFA) Task Force for therapy studies 
(QMG score) [27] and contains similar sub scores (except 
hand-held dynamometer measurements). When using dis-
ease severity as a categorical value, patients demonstrating a 
relative Besinger score ≥ 0.5 were considered as having high 
disease severity. For the comparison of thymectomy and/or 
azathioprine-treated/untreated MG patients, only patients 
that did not receive further immunomodulatory treatment 
were considered for the analysis (n = 20 non-thymectomized 
versus n = 4 thymectomized; n = 27 azathioprine-untreated 
versus n = 12 azathioprine-treated).
Serum anti‑AChR autoantibody level measurement
Serum patient anti-AChR autoantibodies were measured at 
the Department of Clinical Immunology (University Hospi-
tal, Zurich) using an 125I radioimmunoassay based on reac-
tivity against fetal and adult nicotinic AChR (DLD Diagnos-
tika), as part of the routine diagnostic procedure.
Leukocyte isolation from blood and thymic tissue
Blood samples were diluted in PBS and PBMC fraction was 
isolated using SepMate 50 tubes (Stemcell Technologies) 
and human Lympholyte Separation Medium (Cedarlane). 
To ensure comparability with PBMC samples, a similar pro-
tocol for thymic leukocyte isolation was chosen. In brief, 
thymic tissue was placed on ice immediately after surgery 
and processed. A single-cell suspension was achieved by 
cutting the tissue using a scalpel and syringes. The cell sus-
pension was washed and the leukocyte fraction isolated by 
density gradient centrifugation using human Lympholyte 
Separation Medium (Cedarlane). The resulting lymphocyte 
fraction was washed, cryopreserved in 10% DMSO in fetal 
calf serum (FCS; Biochrom) and stored in the vapor phase 
of a liquid nitrogen tank until further analysis.
Ex vivo reactivation of PBMCs
Short-term reactivation of cryopreserved PBMCs or 
thymic leukocytes and subsequent cytometry analysis 
were performed as described previously [22]. In short, 
leukocytes were stored in liquid nitrogen and thawed in 
a 37 °C water bath before use. Cells were resuspended in 
cell culture medium [RPMI-1640, 10% FCS (Biochrom), 
and 1 × L-glutamine and 1 × penicillin/streptomycin (both 
Life Technologies)] supplemented with 1:10,000 benzo-
nase (Sigma–Aldrich), centrifuged (300×g, 7 min; 24 °C) 
and washed twice with cell culture medium. Samples then 
underwent antibody labeling, or in the case of intracel-
lular cytokine detection, were rested overnight at 37 °C 
and restimulated with 50 ng   ml−1 phorbol 12-myristate 
13-acetate (Sigma–Aldrich) and 500 ng  ml−1 ionomycin 
(Sigma–Aldrich) in the presence of 1 × Brefeldin A and 
1 × Monensin (both BD Biosciences) for 4 h at 37 °C before 
surface marker antibody labeling, fixation, permeabilization 
and intracellular cytokine antibody labeling.
Antibodies
For mass cytometry, monoclonal anti-human antibodies 
(Supplementary Table 1) were purchased either conjugated 
to heavy-metal isotopes (Fluidigm) or were conjugated in 
house using the MaxPar X8 chelating polymer kit (Fluid-
igm). Flow cytometry antibodies were purchased already 
conjugated to the specified fluorochromes (Supplementary 
Table 2).
Live cell barcoding for mass cytometry
To reduce inter-sample staining variability, minimize sam-
ple-handling time, and reduce instrument performance-based 
signal variation, we made use of a combinatorial live-cell 
barcoding approach using differentially conjugated anti-
CD45 mAbs (Biolegend). MaxPar X8 polymers (Fluidigm) 
were loaded with six different palladium isotopes (102Pd, 
104Pd, 105Pd, 106Pd, 108Pd, and 110Pd) and one indium 
isotope (115In; all from Trace Sciences International) and 
conjugated to anti-human CD45 mAbs (BioLegend). To 
exclude doublets and prevent misidentification of barcodes 
during debarcoding, a restricted 7-choose-3 approach was 
applied, resulting in 35 barcodes per mass cytometry run. 
Independent mass cytometry runs contained equal ratios of 
MG patients and healthy controls and were subject to rand-
omization with regards to treatment, sex, and age. PBMCs 
were labeled with heavy metal-tagged CD45 antibodies 
after ex vivo reactivation at 37 °C for 25 min in cell-staining 
medium (CSM; RPMI-1640, 4% FCS) on an orbital shaker 
(500 rpm). Samples were washed twice in CSM and com-
bined into a single reaction vessel for surface marker and 
cytokine detection.
Surface and intracellular cytokine detection by mass 
cytometry
The barcoded sample convolute was labeled in 400 μl CSM 
containing the antibody mix directed against surface markers 
for 40 min at 37 °C on an orbital shaker (500 rpm). For dead 
cell discrimination, 2.5 μM cisplatin (Sigma-Aldrich) was 
added for 2 min on ice.
For transcription factor detection, the sample convo-
lute was fixed and permeabilized for 40 min at 4 °C in 1X 
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FOXP3 Fixation/Permeabilization Buffer (BioLegend). 
Sample was washed in permeabilization buffer [(PBS, 0.5% 
saponin, 2% bovine serum albumin (BSA), 0.01% sodium 
azide (all Sigma-Aldrich)] and nuclear staining was per-
formed in 400 μl permeabilization buffer for 1 h at 4 °C.
For intracellular cytokine detection the sample convolute 
was fixed in 1.6% paraformaldehyde (Electron Microscopy 
Sciences) for 1 h at 4 °C. The convolute was washed with 
permeabilization buffer and labeled with antibodies recog-
nizing intracellular cytokines in 400 μl permeabilization 
buffer for 1 h at 4 °C.
In both the cases, the labeled and stained sample mix was 
washed and resuspended in 1X iridium intercalator solution 
(Fluidigm) followed by a 4 °C incubation overnight. Finally, 
the sample was washed twice with PBS and twice with Max-
Par water (Fluidigm) before data acquisition.
Flow cytometry sample labeling and data 
acquisition
Flow cytometry labeling was performed similarly as for 
mass cytometry. In brief, samples were labeled with 100 μl 
of a fluorochrome-conjugated antibody mix in PBS for 
20 min at 4 °C and washed twice in PBS. For intracellular 
cytokine detection, samples were fixed for 20 min at 4 °C 
using 100 μl Cytofix/Cytoperm (BD Biosciences). Cytokine 
staining was performed in 100 µl antibody mix in permeabi-
lization buffer at 4 °C overnight. Samples were washed twice 
and acquired at a Cytek Aurora Spectral Analyzer (Cytek 
Bioscience). Quality control on a daily basis ensured reli-
ability and reproducibility of the machine’s performance.
Compensation matrix was corrected in FlowJo (TreeS-
tar) and samples were gated into live  CD45+ singlets and 
exported to the R analysis framework.
Mass cytometry acquisition and data preprocessing
Barcoded and labeled sample data were acquired on a 
CyTOF 2.1 mass cytometer (Fluidigm). Instrument quality 
control and tuning was performed on a daily basis. Acqui-
sitions from two independent runs were normalized using 
five-element beads (Fluidigm) [15]. To further control for 
batch effects, each independent run contained one normali-
zation control sample that was present in both runs. Live 
single cells in the sample convolute were identified based on 
event length, center, width, DNA (191Ir and 193Ir) and live/
dead (195Pt) channels in FlowJo (TreeStar). Debarcoding was 
achieved by Boolean gating in FlowJo of cells exclusively 
bearing three barcodes. Both flow and mass cytometry data 
were transformed in the R environment using an inverse 
hyperbolic sine (arcsin) function. In case individual mark-
ers were not aligned in the normalization controls of both 
mass cytometry runs due to residual batch effects, cofactors 
of the sample convolute were adapted to achieve the same 
mean in staining intensity for both normalization controls. 
A channel-based percentile normalization using the 99.9th 
percentile was further applied on the transformed dataset 
for flow and mass cytometry data. Cytokine positivity was 
determined in an automated fashion by calculating the 99th 
percentile of the residual cytokine labeling of an unstimu-
lated control.
Immunohistochemistry
Thymus tissue samples were cryosectioned for immunohis-
tochemistry using a Hyrax C60 cryostat (Zeiss). Thymus 
sections (10 μm) were fixed with 2% (wt/vol) paraformal-
dehyde (PFA) in 0.1 M phosphate buffer, pH 7.4, and ace-
tone, washed in PBS, and blocked with PBS supplemented 
with 0.1% Triton X-100 and 4% normal goat serum. Subse-
quently, sections were incubated with the following primary 
antibodies (diluted in blocking solution) overnight at 4 °C: 
rat anti-GM-CSF antibody (BD Pharmingen, clone BVD2-
21C11, 1:50), mouse anti-CD4 antibody (Biolegend, clone 
RPA-T4, 1:50) and rabbit anti-CD3 (NOVUS, clone SP7, 
1:100). Sections were then washed in PBS and incubated 
with AF647-labeled goat anti-rat, AF488-labeled goat anti-
mouse and AF555-labeled goat anti-rabbit secondary anti-
bodies (Life Technologies, 1:500) overnight at 4 °C. Sec-
tions were mounted with SlowFade Gold antifade reagent 
with DAPI (Invitrogen). Fluorescence photomicrographs 
were captured with a SP5 Leica confocal laser scanning 
microscope (SP5; Leica) equipped with argon and helium 
lasers using the 40 × objective lens (oil immersion, NA1.25). 
Images were processed and merged by Imaris imaging soft-
ware (Bitplane).
Multiplexed immunofluorescence
Multispectral immunofluorescence was performed apply-
ing the following antibody panel to Formalin-fixed paraf-
fin-embedded tissue sections of thymus and normal tonsil 
tissues: CD3 (Leica Microsystems Ltd, clone LN10, 1:50), 
CD4 (Leica Microsystems Ltd, clone 4B12, 1:50), CD20 
(Leica Microsystems Ltd, clone L26, 1:200), CD23 (Leica 
Microsystems Ltd, clone 1B12, RTU), CD103 (Abcam, 
clone EPR4166(2), 1:500), Cytokeratin (Agilent Technolo-
gies, clone AE1/AE3, 1:100), and counterstaining with 
DAPI. The optimized multiplexed immunofluorescence 
protocols were validated against chromogenic singleplex 
protocols on consecutive sections of a normal human reac-
tive tonsil tissue and thymus samples. Prior to staining, all 
tissue slides were deparaffinised on the Leica BOND RX 
automated immunostainer (Leica Microsystems) by soaking 
in BOND Dewax solution at 72 °C and then rehydrating in 
ethanol. Tyramide signal amplification-based Opal method 
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was used in this study for immunofluorescence (IF) staining 
(Opal 7-Color Automation IHC Kit, Akoya Biosciences). 
The primary antibody conditions and order of staining 
determined using DAB detection were directly applied to 
the fluorescent assays. Unlike conventional immunohisto-
chemistry, a chromogenic peroxidase substrate is used for 
antigen detection, each antibody is paired with an individual 
Opal fluorophore for visualization. Importantly, if biomark-
ers were expected to co-localize in the same cellular com-
partment then they were paired with spectrally separated 
Opals. In addition, low expressing markers were coupled to 
more intense Opals to facilitate spectral acquisition, and vice 
versa. The Opal fluorophores were used at a 1/100 to 1/200 
dilutions. As such, a fluorescent singleplex was performed 
for each biomarker and compared to the appropriate chromo-
genic singleplex to assess staining performance.
All fluorescently labeled slides were scanned on the 
Vectra 3 at 20 × magnification using appropriate exposure 
times. Initially, whole slide images were scanned with all 
five standard epi-fluorescence filters (DAPI, FITC, Cy3, 
Texas Red and Cy5). Then, when MOTiF Opals were solely 
used, images were acquired using tile scanning with the mIF 
whole slide unmixing filters (DAPI + Opal 570/690, Opal 
480/620/780, and Opal 520). Library slides were gener-
ated from representative tissue sections to allow for accu-
rate unmixing of the multiplexed samples, including a slide 
stained for each single fluorophore, a DAPI only slide, and 
an autofluorescence slide wherein no antibody, Opal reagent 
or DAPI was applied. For quantification of tissue sections, 
cells were segmented based on the DAPI signal using the 
inForm 2.3 software (PerkinElmer) and imported into the 
statistical programming environment R. Downstream analy-
sis including transformation, dimensionality reduction and 
cell clustering was carried out analogous to the cytometry 
analysis described below.
In addition, for individual representative CD103 stainings 
of thymi, immunohistochemistry was performed using the 
two-step IHC staining kit EnVision + System HRP DAKO 
(Glostrup, Denmark) according to the manufacturer’s 
instructions. Sections underwent heat-mediated antigen 
retrieval with Dako Target Retrieval Solution. DAB was 
used as the chromogen, and the sections counterstained 
with haematoxylin and analyzed with the light microscope 
Olympus BX41.
Algorithm‑guided high‑dimensional analysis
The high-dimensional analysis was accomplished in the R 
environment. For FlowSOM clustering, 100 clusters were 
generated from the combined dataset and metaclustered 
based on the elbow point. The elbow point was deter-
mined by plotting the percentage of variance explained in 
relation to the number of metaclusters using the package 
ConsensusClusterPlus. UMAPs were generated using the 
R package umap with default settings [34]. Force-directed 
layouts were generated using the ForceAtlas2 algorithm 
[26] integrated in the VorteX graphical clustering environ-
ment creating unweighted edges between the nodes based 
on the 10 nearest neighbors [36]. Resulting graphs were 
further modified using the Gephi Toolkit 0.9.2. Scaffold 
networks were created using the improved version of the 
initial Scaffold package consisting of grappolo, vite and 
panorama [39]. Mass cytometry FlowSOM nodes of the 
peripheral blood were used to create the landmark nodes. 
All plots and visualizations were drawn using the ggplot2 
package.
Statistical analysis
Immune cell frequencies were compared using the 
unpaired nonparametric Mann–Whitney–Wilcoxon test 
using the stats package. To correct for multiple testing, 
the Benjamini–Hochberg correction was applied [3]. Lin-
ear regression analysis was carried out using the R base 
function lm.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00401- 021- 02299-y.
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